The History of Parkinson's Disease: Early Clinical Descriptions and Neurological Therapies

Anti-Parkinson’s Activity of Uncaria Rhynchophylla Extract on Rotenone Induced Parkinsonism Model in Male Albino Rats

“…In current study, TH reduction and subsequent DA reduction were observed in rotenone injected group. This may be attributed to the negative effect of alpha-synuclein in PD [29]. This enzyme is a rate limiting step in the biosynthesis of catecholamines that catalyzes the conversion of tyrosine to L-DOPA, the precursor of dopamine, which is in turn converted into noradrenalin by dopamine-β-hydroxylase [30] The loss in TH activity and expression is thought to contribute to the L-DOPA deficiency observed in parkinson's disease [31].…”

The Receptor for Advanced Glycation Endproducts (RAGE) and Mediation of Inflammatory Neurodegeneration

“…Parkinson's disease (PD) is another common neurodegenerative disorder that impacts millions of people worldwide and is characterized by the specific loss of nigrostriatal dopaminergic neurons and locomotor deficits [88]. While the cerebral location and neuronal subsets that degenerate in PD are distinct from AD, there are prominent cellular activation mechanisms driving inflammation and perturbation of neurons at the nexus of the two disorders.…”

Nano-Carriers: An Emerging Trend for Brain Tumor Treatment. A Frontier Look

“…[53, [61][62][63][64][65][66][67][68][69][70][71] The types of nanoparticles include polymeric, ceramic and metallic matrixes, polymeric micelles, liposomes and dendrimers. [72] For cancer imaging, various types of nanoparticles have been investigated for MRI, optical imaging and ultrasound imaging.…”